Financials

Company Profile

November 26, Inc., formerly BIOLASE, Inc., is not engaged in any business activities. The Company has no assets.

Employees

157

Sector

Market Closed - Deutsche Boerse AG Other stock markets 09:10:06 21/06/2024 +03			5-day change	1st Jan Change
0.0100 ^EUR	-71.43%		-.--%	-

27/08/25	MegaGen Implant Co., Ltd. acquired All Assets of BIOLASE, Inc from BIOLASE, Inc. (OTCPK:BIOL.Q).	CI
19/05/25	EnVVeno Medical Names Jennifer Bright CFO	MT

27/08/25	MegaGen Implant Co., Ltd. acquired All Assets of BIOLASE, Inc from BIOLASE, Inc. (OTCPK:BIOL.Q).	CI
19/05/25	EnVVeno Medical Names Jennifer Bright CFO	MT
05/03/25	Motion for Asset Sale Approved for BIOLASE, Inc.	CI
25/02/25	Second Amended Combined Liquidation Plan & Disclosure Approved for BIOLASE, Inc.	CI
21/02/25	Second Amended Combined Liquidation Plan & Disclosure Statement Filed by BIOLASE, Inc.	CI
18/02/25	Motion for Exclusivity Period Extension Approved For BIOLASE, Inc.	CI
14/02/25	Motion for Asset Sale Filed by BIOLASE, Inc.	CI
29/01/25	First Motion for Exclusivity Period Extension Filed by BIOLASE, Inc.	CI
14/01/25	First Amended Disclosure Statement Approved on Interim Basis for BIOLASE, Inc.	CI
13/01/25	First Amended Combined Liquidation Plan and Disclosure Statement Filed by BIOLASE, Inc.	CI
08/01/25	Disclosure Statement Conditionally Approved for BIOLASE, Inc.	CI
23/12/24	Combined Liquidation Plan and Disclosure Statement Filed by BIOLASE, Inc.	CI
15/11/24	Motion for Asset Sale Approved for BIOLASE, Inc.	CI

01/04/24	Ascendiant Capital Adjusts Biolase's Price Target to $4 From $15, Reiterates Buy Rating	MT
31/05/23	Lake Street Adjusts Price Target on Biolase to $0.40 From $1.50, Maintains Buy Rating	MT
20/01/23	Lake Street Assumes Biolase at Buy With $1.50 Price Target	MT
20/05/22	Lake Street Initiates Biolase at Buy, Sets Price Target at $12	MT

14/10/25	BIOLASE Showcases Breakthrough YSGG Laser Protocol for Predictable Periodontitis Treatment at AAP 2025	PR
08/11/24	Biolase: Q3 Earnings Snapshot	AQ
08/11/24	BIOLASE : Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q)	PU
01/10/24	BIOLASE : Voluntarily Initiates Chapter 11 Proceedings Form 8 K	PU
08/08/24	Biolase: Q2 Earnings Snapshot	AQ

Manager	Title	Age	Since
Gwang-Bum Park CEO	Chief Executive Officer	65	10/09/2025
Steven Sandor COO	Chief Operating Officer	46	06/07/2022
Samuel B. Low CTO	Chief Tech/Sci/R&D Officer	-	01/10/2016

Director	Title	Age	Since
Jonathan Lord CHM	Chairman	71	01/09/2017
Kathleen O'Loughlin BRD	Director/Board Member	75	16/08/2021
Kenneth Yale BRD	Director/Board Member	69	28/04/2022

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOLASE, INC.	-71.43%	-.--%	-	-	36
CHURCHILL CAPITAL CORP XI	-0.96%	-6.95%	-	-	806M
DRUGS MADE IN AMERICA ACQUISITION II CORP.	-0.10%	-0.20%	-	-	642M
DEEP FISSION, INC.	+1.33%	-4.14%	-	-	643M
CHURCHILL CAPITAL CORP XII	+0.56%	+0.85%	-	-	611M
CANTOR EQUITY PARTNERS IV, INC.	-0.14%	-0.05%	-	-	596M
BAIN CAPITAL GSS INVESTMENT CORP.	-0.10%	-0.44%	-	-	596M
AMERICAN EXCEPTIONALISM ACQUISITION CORP. A	-1.53%	-1.53%	-	-	575M
CENTIEL AG	-2.80%	+8.17%	+241.94%	-71.63%	563M
Average	-8.35%	-0.54%	+241.94%	-71.63%	628.96M
Weighted average by Cap.	-0.44%	-0.88%	+241.94%	-71.63%